Previous 10 | Next 10 |
Enzo Biochem press release (NYSE:ENZ): Q3 GAAP EPS of -$0.10. Revenue of $26.2M (-20.1% Y/Y). Adjusted EBITDA loss in the 3Q of $1.8M, compared to adjusted EBITDA of $2.7M in the 3Q of 2021. Cash and cash equivalents, restricted cash and marketable securities totaled $32.1 million as of April...
Third quarter revenue of $26.2 million declined sequentially and year over year due to the anticipated waning of COVID-19 volumes and the economic shutdowns in Asia Received approval from New York State Department of Health for its AMPIPROBE® HPV Molecular Diagnostic tests ...
CMTL, DOCU, ENZ, LAKE, MTN, SFIX For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close
NEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a li...
Conference Call and Webcast Scheduled for June 9, 2022, 4:30 pm ET NEW YORK, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Th...
The shares of Enzo Biochem (NYSE:ENZ) have added ~9% in the pre-market after the health services company announced that the New York State Department of Health (DOH) had approved its AMPIPROBE HPV test. There is a link between many cervical cancers and infection with high-risk human papi...
NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE ...
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced the approval of all p...
Meeting Scheduled for April 8, 2022 at 9:00 AM ET NEW YORK, NY, April 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, held its Annual Shareholder Meeting (the “An...
NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Pro...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's...
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fis...